Both inhibitors of JAK (baricitinib, tofacitinib, and ruxolitinib) [11, 14, 15] and TGF-β (neutralizing anti-TGF-β1 antibodies such as fresolimumab and IgG4κ monoclonal antibody and TGF-β receptor kinase inhibitors like galunisertib and vactosertib) mitigate inflammation in DKD [87–89]. Here, TGFB1 is linked to diabetic kidney disease.